Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2017-03-30 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Change in Pricing and Billing Program 2 pages 78.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 31 March 2017 from Genetic Technologies Limited regarding a change in the pricing and billing program for their product BREVAGen plus. It discusses strategic business decisions and pricing changes but does not contain financial statements, earnings data, or detailed financial analysis. It is a corporate announcement about a business strategy update rather than a financial report or regulatory filing. The document length is 7,253 characters, which is sufficient for a detailed announcement but does not indicate a full report. There is no indication of it being an earnings release, annual or interim report, or any other financial filing. Therefore, the document best fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement or miscellaneous filing that does not fit other specific categories.
2017-03-30 English
Partnership to Promote BREVAGenplus, Second Year 2 pages 96.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29 March 2017 from Genetic Technologies Limited. It details a marketing partnership with IndyCar driver Pippa Mann to promote the company's product BREVAGen plus. The content focuses on promotional activities, partnership details, and background information about the company and the athlete. There are no financial statements, regulatory filings, voting results, or management changes discussed. The document is a corporate announcement about a marketing partnership rather than a financial report, regulatory filing, or governance document. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate announcement, which corresponds to Regulatory Filings (RNS). The document length is 7084 characters, which is sufficient for a full announcement but does not contain financial data or report content. Hence, the classification is RNS with high confidence.
2017-03-28 English
Appendix 4D and 31 December 2016 Half Year Financial Report 22 pages 6.6MB
Regulatory Filings
2017-02-22 English
Employee Share Options Issued & Forfeited 14 pages 183.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an ASX announcement dated 20 February 2017 regarding the issuance and forfeiture of employee share options by Genetic Technologies Limited. It includes detailed information about the number of options issued, exercise prices, expiry dates, and references to the company's employee option plan. The document also contains an Appendix 3B, which is a standard form used in Australian securities markets for new issue announcements and applications for quotation of additional securities. The content focuses on share option issuance and related capital changes rather than financial results, management changes, or other report types. The document is lengthy (15,000 characters) and contains substantive details about the securities issued, not merely an announcement of a report or a certification. Therefore, the most appropriate classification is a Share Issue/Capital Change (SHA) filing, as it relates to new share options issued and capital structure changes.
2017-02-19 English
Quarterly Activities Report & Appendix 4C - 31 December 2016 10 pages 1.5MB
Regulatory Filings
2017-01-26 English
Capital Raising Update & Appendix 3B 12 pages 159.2KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement dated 6 December 2016 regarding a capital raising update by Genetic Technologies Limited. It includes detailed information about the allotment of new ordinary shares, the number of shares issued, issue price, purpose of the issue, and compliance with ASX rules. The document is an Appendix 3B form, which is a standard new issue announcement form used by companies listed on the ASX to notify the market of new securities issued. The content focuses on the capital raising event and the issuance of new shares, not on financial results, management changes, or other report types. The document length is about 15,000 characters, containing substantive details about the capital raising and share issuance. Therefore, this document fits the category of Capital/Financing Update (CAP).
2016-12-05 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.